50
Participants
Start Date
July 9, 2025
Primary Completion Date
January 31, 2026
Study Completion Date
August 31, 2026
GLM101 (Part A, Double-blind)
IV infusions, 30 mg/kg once weekly for 24 weeks, for participants randomized to GLM101 in Part A
Placebo (Part A, Double-blind)
IV infusions, 30 mg/kg once weekly for 24 weeks, for participants randomized to Placebo in Part A
GLM101 (Part B, Open-label)
IV infusions, 30 mg/kg once weekly from week 25 to 48, to all participants
RECRUITING
UZ Leuven, Campus Gasthuisberg, Leuven
RECRUITING
Icahn School of Medicine at Mount Sinai, New York
RECRUITING
The Children's Hospital of Philadelphia, Philadelphia
NOT_YET_RECRUITING
Hospital Universitario 12 de Octubre, Madrid
NOT_YET_RECRUITING
Universitaetsklinikum Muenster, Münster
NOT_YET_RECRUITING
University of Minnesota, Minneapolis
NOT_YET_RECRUITING
Azienda Ospedaliero Universitaria Pisana, Pisa
RECRUITING
AP-HP Hopital Necker-Enfants Malades, Paris
RECRUITING
Azienda Ospedaliero Universitaria Policlinico G. Rodolico-San Marco, Catania
RECRUITING
Seattle Children's Hospital, Seattle
RECRUITING
Vseobecna fakultni nemocnice v Praze, Prague
NOT_YET_RECRUITING
Instytut Matki i Dziecka, Warsaw
RECRUITING
Unidade Local de Saúde de Santo António, Porto
RECRUITING
Hospital Sant Joan de Déu, Esplugues de Llobregat
RECRUITING
Birmingham Women's and Children's NHS Foundation Trust, Birmingham
NOT_YET_RECRUITING
Great Ormond Street Hospital, London
Lead Sponsor
Glycomine, Inc.
INDUSTRY